Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
OwnerJohan Wilhelm Stjernschantz, Bahram Resulinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to opthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an opthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Claims2
A therapeutic composition for topical treatment of ocular hypertension containing a prostaglandin PGA, PGB, PGE or PGF in an amount sufficient to reduce intraocular pressure without causing substantial intraocular irritation and an opthamologically compatible vehicle
- wherein
- the omega chain of the prostaglandin has the formula C13-B-C14-D-R2
- wherein
- C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);
- B is a single bond, double bond or triple bond;
- D is a subchain comprising 3 carbon atoms and 0-2 heteroatoms selected from the group consisting of O,N and S, having a substitutent on each subchain atom selected from the group consisting of a hydrogen atom, an alkyl group, oxo group and a hydroxyl group;
- and
- R2 is 17 phenyl which is unsubstituted or has at least one substitutent selected from the group consisting of
- C1-C5 alkyl groups,
- C1-C4 alkoxy groups,
- trifluoromethyl groups,
- C1-C3 aliphatic acylamino groups,
- nitro groups, and
- a phenyl group.
Dependencies are inferred from the claim text.